3,4-Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: β-ketoamphetamine modulation of neurotoxicity by the dopamine transporter

Journal of Neurochemistry

Volumn 133, Issue 2, 2015, Pages 211-222

  Anneken, John H ^a,b   Angoa Pérez, Mariana ^a,b   Kuhn, Donald M ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

dopamine nerve ending; dopamine transporter; neurotoxic amphetamines; neurotoxicity; ketoamphetamines

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYPYROVALERONE; 4' METHYLMETHCATHINONE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; BETA KETOAMPHETAMINE; DOPAMINE; DOPAMINE TRANSPORTER; GLIAL FIBRILLARY ACIDIC PROTEIN; METHAMPHETAMINE; METHYLONE; PSYCHOTROPIC AGENT; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; 3,4-METHYLENEDIOXYPYROVALERONE; CENTRAL STIMULANT AGENT; NEUROTOXIN; PYRROLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; FEMALE; HYPERTHERMIA; MOUSE; NERVE CELL LESION; NERVE ENDING; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; BODY TEMPERATURE; C57BL MOUSE; CORPUS STRIATUM; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM;

MUSCOVY DUCK PARVOVIRUS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BENZODIOXOLES; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; NERVE ENDINGS; NEUROTOXINS; PSYCHOTROPIC DRUGS; PYRROLIDINES; TYROSINE 3-MONOOXYGENASE;

EID: 84926614433     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13048     Document Type: Article

References (59)

1. Aarde S. M., Angrish D., Barlow D. J., Wright M. J., Jr, Vandewater S. A., Creehan K. M., Houseknecht K. L., Dickerson T. J., and, Taffe M. A., (2013a) Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addict. Biol. 18, 786-799.
2. Aarde S. M., Huang P. K., Creehan K. M., Dickerson T. J., and, Taffe M. A., (2013b) The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology 71C, 130-140.
3. Angoa-Perez M., Kane M. J., Francescutti D. M., Sykes K. E., Shah M. M., Mohammed A. M., Thomas D. M., and, Kuhn D. M., (2012) Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J. Neurochem. 120, 1097-1107.
4. Angoa-Perez M., Kane M. J., Briggs D. I., Francescutti D. M., Sykes C. E., Shah M. M., Thomas D. M., and, Kuhn D. M., (2013) Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA. J. Neurochem. 125, 102-110.
5. Angoa-Perez M., Kane M. J., Herrera-Mundo N., Francescutti D. M., and, Kuhn D. M., (2014) Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus. Life Sci. 97, 31-36.
6. Baumann M. H., Ayestas M. A., Jr, Partilla J. S., Sink J. R., Shulgin A. T., Daley P. F., Brandt S. D., Rothman R. B., Ruoho A. E., and, Cozzi N. V., (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37, 1192-1203.
7. Baumann M. H., Partilla J. S., Lehner K. R., et al,. (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology 38, 552-562.
8. Bonano J. S., Glennon R. A., De Felice L. J., Banks M. L., and, Negus S. S., (2014) Abuse-related and abuse-limiting effects of methcathinone and the synthetic "bath salts" cathinone analogs methylenedioxy-pyrovalerone (MDPV), methylone and mephedrone on intracranial self-stimulation in rats. Psychopharmacology 231, 199-207.
9. Cameron K., Kolanos R., Vekariya R., De Felice L., and, Glennon R. A., (2013a) Mephedrone and methylenedioxypyrovalerone (MDPV), major constituents of "bath salts", produce opposite effects at the human dopamine transporter. Psychopharmacology 227, 493-499.
10. Cameron K. N., Kolanos R., Solis E., Jr, Glennon R. A., and, De Felice L. J., (2013b) Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br. J. Pharmacol. 168, 1750-1757.
11. Coppola M., and, Mondola R., (2012) 3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol. Lett. 208, 12-15.
12. Elkashef A. M., Rawson R. A., Anderson A. L., et al,. (2008) Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 33, 1162-1170.
13. Eshleman A. J., Wolfrum K. M., Hatfield M. G., Johnson R. A., Murphy K. V., and, Janowsky A., (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem. Pharmacol. 85, 1803-1815.
14. Fantegrossi W. E., Gannon B. M., Zimmerman S. M., and, Rice K. C., (2013) In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity. Neuropsychopharmacology 38, 563-573.
15. Gatch M. B., Taylor C. M., and, Forster M. J., (2013) Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones. Behav. Pharmacol. 24, 437-447.
16. Gregg R. A., Tallarida C. S., Reitz A., McCurdy C., and, Rawls S. M., (2013a) Mephedrone (4-methylmethcathinone), a principal constituent of psychoactive bath salts, produces behavioral sensitization in rats. Drug Alcohol Depend. 133, 46-50.
17. Gregg R. A., Tallarida C. S., Reitz A. B., and, Rawls S. M., (2013b) Mephedrone interactions with cocaine: prior exposure to the 'bath salt' constituent enhances cocaine-induced locomotor activation in rats. Behav. Pharmacol. 24, 684-688.
18. Hadlock G. C., Webb K. M., McFadden L. M., et al,. (2011) 4-Methylmethcathinone(mephedrone): neuropharmacological effects of a designer stimulant of abuse. J. Pharmacol. Exp. Ther. 339, 530-536.
19. Halpin L. E., Collins S. A., and, Yamamoto B. K., (2014) Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci. 97, 37-44.
20. Hill S. L., and, Thomas S. H., (2011) Clinical toxicology of newer recreational drugs. Clin. Toxicol. 49, 705-719.
21. den Hollander B., Rozov S., Linden A. M., Uusi-Oukari M., Ojanpera I., and, Korpi E. R., (2013) Long-term cognitive and neurochemical effects of "bath salt" designer drugs methylone and mephedrone. Pharmacol. Biochem. Behav. 103, 501-509.
22. den Hollander B., Sundstrom M., Pelander A., Ojanpera I., Mervaala E., Korpi E. R., and, Kankuri E., (2014) Keto amphetamine toxicity-focus on the redox reactivity of the cathinone designer drug mephedrone. Toxicol. Sci. 141, 120-131.
23. Huang P. K., Aarde S. M., Angrish D., Houseknecht K. L., Dickerson T. J., and, Taffe M. A., (2012) Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats. Drug Alcohol Depend. 126, 168-175.
24. Javitch J. A., D'Amato R. J., Strittmatter S. M., and, Snyder S. H., (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl Acad. Sci. USA 82, 2173-2177.
25. Karlsson L., Andersson M., Kronstrand R., and, Kugelberg F. C., (2014) Mephedrone, methylone and 3,4-methylenedioxypyrovalerone (MDPV) induce conditioned place preference in mice. Basic Clin. Pharmacol. Toxicol. 115, 411-416.
26. Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F., and, Yoshitake T., (2011) Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br. J. Pharmacol. 164, 1949-1958.
27. Kolanos R., Solis E., Jr, Sakloth F., De Felice L. J., and, Glennon R. A., (2013) "Deconstruction" of the abused synthetic cathinone methylenedioxypyrovalerone (MDPV) and an examination of effects at the human dopamine transporter. ACS Chem. Neurosci. 4, 1524-1529.
28. Kuhn D. M., and, Billingsley M. L., (1987) Tyrosine hydroxylase: purification from PC -12 cells, characterization, and production of antibodies. Neurochem. Int. 11, 463-475.
29. Lisek R., Xu W., Yuvasheva E., Chiu Y. T., Reitz A. B., Liu-Chen L. Y., and, Rawls S. M., (2012) Mephedrone ('bath salt') elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depend. 126, 257-262.
30. Lopez-Arnau R., Martinez-Clemente J., Pubill D., Escubedo E., and, Camarasa J., (2012) Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br. J. Pharmacol. 167, 407-420.
31. Lopez-Arnau R., Martinez-Clemente J., Abad S., Pubill D., Camarasa J., and, Escubedo E., (2014) Repeated doses of methylone, a new drug of abuse, induce changes in serotonin and dopamine systems in the mouse. Psychopharmacology 231, 3119-3129.
32. Martinez-Clemente J., Lopez-Arnau R., Abad S., Pubill D., Escubedo E., and, Camarasa J., (2014) Dose and time-dependent selective neurotoxicity induced by mephedrone in mice. PLoS ONE 9, e99002.
33. Marusich J. A., Grant K. R., Blough B. E., and, Wiley J. L., (2012) Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice. Neurotoxicology 33, 1305-1313.
34. Marusich J. A., Antonazzo K. R., Wiley J. L., Blough B. E., Partilla J. S., and, Baumann M. H., (2014) Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87, 206-213.
35. Miller B. L., and, Stogner J. M., (2014) Not-so-clean fun: a profile of bath salt users among a college sample in the United States. J. Psychoactive Drugs 46, 147-153.
36. Miller M. L., Creehan K. M., Angrish D., Barlow D. J., Houseknecht K. L., Dickerson T. J., and, Taffe M. A., (2013) Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). Drug Alcohol Depend. 127, 248-253.
37. Miotto K., Striebel J., Cho A. K., and, Wang C., (2013) Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend. 132, 1-12.
38. Motbey C. P., Hunt G. E., Bowen M. T., Artiss S., and, McGregor I. S., (2012a) Mephedrone (4-methylmethcathinone, 'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict. Biol. 17, 409-422.
39. Motbey C. P., Karanges E., Li K. M., et al,. (2012b) Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion. PLoS ONE 7, e45473.
40. Northrop N. A., and, Yamamoto B. K., (2012) Persistent neuroinflammatory effects of serial exposure to stress and methamphetamine on the blood-brain barrier. J. Neuroimmune Pharmacol. 7, 951-968.
41. O'Dell S. J., Weihmuller F. B., and, Marshall J. F., (1993) Methamphetamine-induced dopamine overflow and injury to striatal dopamine terminals: attenuation by dopamine D1 or D2 antagonists. J. Neurochem. 60, 1792-1799.
42. Pifl C., Drobny H., Reither H., Hornykiewicz O., and, Singer E. A., (1995) Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol. Pharmacol. 47, 368-373.
43. Pu C., Fisher J. E., Cappon G. D., and, Vorhees C. V., (1994) The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum. Brain Res. 649, 217-224.
44. Robinson J. E., Agoglia A. E., Fish E. W., Krouse M. C., and, Malanga C. J., (2012) Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL/6J mice: comparison to cocaine. Behav. Brain Res. 234, 76-81.
45. Schmidt C. J., and, Gibb J. W., (1985) Role of the dopamine uptake carrier in the neurochemical response to methamphetamine: effects of amfonelic acid. Eur. J. Pharmacol. 109, 73-80.
46. Shoptaw S., Heinzerling K. G., Rotheram-Fuller E., Steward T., Wang J., Swanson A. N., De La Garza R., Newton T., and, Ling W., (2008) Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend. 96, 222-232.
47. Shortall S. E., Green A. R., Swift K. M., Fone K. C., and, King M. V., (2013a) Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia. Br. J. Pharmacol. 168, 966-977.
48. Shortall S. E., Macerola A. E., Swaby R. T., et al,. (2013b) Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur. Neuropsychopharmacol. 23, 1085-1095.
49. Simmler L. D., Buser T. A., Donzelli M., Schramm Y., Dieu L. H., Huwyler J., Chaboz S., Hoener M. C., and, Liechti M. E., (2013a) Pharmacological characterization of designer cathinones in vitro. Br. J. Pharmacol. 169, 458-470.
50. Simmler L. D., Wandeler R., and, Liechti M. E., (2013b) Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence. BMC Res. Notes 6, 220-224.
51. Spiller H. A., Ryan M. L., Weston R. G., and, Jansen J., (2011) Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin. Toxicol. 49, 499-505.
52. Sulzer D., Sonders M. S., Poulsen N. W., and, Galli A., (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75, 406-433.
53. Thomas D. M., Francescutti-Verbeem D. M., and, Kuhn D. M., (2008) The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J. Neurochem. 105, 605-616.
54. Thomas D. M., Francescutti-Verbeem D. M., and, Kuhn D. M., (2009) Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity. J. Neurochem. 109, 1745-1755.
55. Tiihonen J., Kuoppasalmi K., Fohr J., Tuomola P., Kuikanmaki O., Vorma H., Sokero P., Haukka J., and, Meririnne E., (2007) A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am. J. Psychiatry 164, 160-162.
56. Varner K. J., Daigle K., Weed P. F., Lewis P. B., Mahne S. E., Sankaranarayanan A., and, Winsauer P. J., (2013) Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats. Psychopharmacology 225, 675-685.
57. Watterson L. R., Kufahl P. R., Nemirovsky N. E., Sewalia K., Grabenauer M., Thomas B. F., Marusich J. A., Wegner S., and, Olive M. F., (2012) Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict. Biol. 19, 165-174.
58. Winstock A., Mitcheson L., Ramsey J., Davies S., Puchnarewicz M., and, Marsden J., (2011) Mephedrone: use, subjective effects and health risks. Addiction 106, 1991-1996.
59. Wright M. J., Jr, Angrish D., Aarde S. M., et al,. (2012) Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley rats. PLoS ONE 7, e44652.